Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on February 16, 2004

Circulation. 2004
Published online before print February 16, 2004, doi: 10.1161/01.CIR.0000117254.68497.39
A more recent version of this article appeared on March 9, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/9/1154    most recent
01.CIR.0000117254.68497.39v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engelhardt, S.
Right arrow Articles by Lohse, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engelhardt, S.
Right arrow Articles by Lohse, M. J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
Medline Plus Health Information
*Cardiomyopathy
Related Collections
Right arrow Calcium cycling/excitation-contraction coupling
Right arrow Cell signalling/signal transduction
Right arrow Genetically altered mice
Right arrow Heart failure - basic studies

Submitted on July 18, 2003
Revised on October 24, 2003
Accepted on October 28, 2003

Altered Calcium Handling Is Critically Involved in the Cardiotoxic Effects of Chronic {beta}-Adrenergic Stimulation

Stefan Engelhardt MD, PhD*, Lutz Hein MD, Vitaly Dyachenkow; , Evangelia G. Kranias PhD, Gerrit Isenberg MD, and Martin J. Lohse MD

From the Institute of Pharmacology and Toxicology (S.E., L.H., M.J.L.), University of Wuerzburg, Germany; Institute of Physiology (V.D., G.I.), Martin-Luther-University Halle, Germany; and Department of Pharmacology and Cell Biophysics (E.G.K.), University of Cincinnati College of Medicine, Cincinnati, Ohio.

* To whom correspondence should be addressed. E-mail: stefan.engelhardt{at}virchow.uni-wuerzburg.de.

Background--Chronic adrenergic stimulation leads to cardiac hypertrophy and heart failure in experimental models and contributes to the progression of heart failure in humans. The pathways mediating the detrimental effects of chronic {beta}-adrenergic stimulation are only partly understood. We investigated whether genetic modification of calcium handling through deletion of phospholamban in mice would affect the development of heart failure in mice with transgenic overexpression of the {beta}1-adrenergic receptor.

Methods and Results--We crossed {beta}1-adrenergic receptor transgenic ({beta}1TG) mice with mice homozygous for a targeted deletion of the phospholamban gene (PLB-/-). Phospholamban ablation dramatically enhanced survival of {beta}1TG mice. The decrease of left ventricular contractility typically observed in {beta}1TG mice was reverted back to normal by phospholamban ablation. Cardiac hypertrophy and fibrosis were significantly inhibited in {beta}1TG/PLB-/- mice compared with {beta}1TG mice, and the heart failure-specific gene expression pattern was normalized. Analysis of intracellular calcium transients revealed increased diastolic calcium levels and decreased rate constants of diastolic calcium decline in {beta}1TG mice. In {beta}1TG/PLB-/- mice, diastolic calcium concentration was normal and rate constants of diastolic calcium decline were greater than in wild-type mice.

Conclusions--We conclude that modification of abnormal calcium handling in {beta}1TG mice through ablation of phospholamban resulted in a rescue of functional, morphological, and molecular characteristics of heart failure in {beta}1-adrenergic receptor-transgenic mice. These results imply altered calcium handling as critical for the detrimental effects of {beta}1-adrenergic signaling.


Key words: calcium • heart failure • sarcoplasmic reticulum • hypertrophy • heart failure




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. R. Waggoner, K. S. Ginsburg, B. Mitton, K. Haghighi, J. Robbins, D. M. Bers, and E. G. Kranias
Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H698 - H703.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. P. Schmitt, F. Ahmad, K. Lorenz, L. Hein, S. Schulz, M. Asahi, D. H. MacLennan, C. E. Seidman, J.G. Seidman, and M. J. Lohse
Alterations of Phospholamban Function Can Exhibit Cardiotoxic Effects Independent of Excessive Sarcoplasmic Reticulum Ca2+-ATPase Inhibition
Circulation, January 27, 2009; 119(3): 436 - 444.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. C. Lai, T. Tang, M. H. Gao, M. Saito, T. Takahashi, D. M. Roth, and H. K. Hammond
Activation of Cardiac Adenylyl Cyclase Expression Increases Function of the Failing Ischemic Heart in Mice
J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1490 - 1497.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
H. Ly, Y. Kawase, R. Yoneyama, and R. J. Hajjar
Gene Therapy in the Treatment of Heart Failure
Physiology, April 1, 2007; 22(2): 81 - 96.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Merkle, S. Frantz, M. P. Schon, J. Bauersachs, M. Buitrago, R. J.A. Frost, E. M. Schmitteckert, M. J. Lohse, and S. Engelhardt
A Role for Caspase-1 in Heart Failure
Circ. Res., March 16, 2007; 100(5): 645 - 653.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Yang, W.-Z. Zhu, M.-l. Joiner, R. Zhang, C. V. Oddis, Y. Hou, J. Yang, E. E. Price, L. Gleaves, M. Eren, et al.
Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3065 - H3075.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
D. W. McGraw, K. M. Fogel, S. Kong, A. A. Litonjua, E. G. Kranias, B. J. Aronow, and S. B. Liggett
Transcriptional response to persistent {beta}2-adrenergic receptor signaling reveals regulation of phospholamban, which alters airway contractility
Physiol Genomics, October 11, 2006; 27(2): 171 - 177.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. A. Ashley, J. Powers, M. Chen, R. Kundu, T. Finsterbach, A. Caffarelli, A. Deng, J. Eichhorn, R. Mahajan, R. Agrawal, et al.
The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo
Cardiovasc Res, January 1, 2005; 65(1): 73 - 82.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Tang, M. H. Gao, D. M. Roth, T. Guo, and H. K. Hammond
Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1906 - H1912.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo
Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence
Cardiovasc Res, August 15, 2004; 63(3): 373 - 380.
[Abstract] [Full Text] [PDF]